Actionnariat et activité des initiés pour KALA BIO, Inc. (KALA): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $0.52 |
| Capitalisation | $10M |
| Bourse | NASDAQ |
| Pays | US |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $45.5M | $114.6M | $170.9M | $85.4M | $77.3M | $92.1M | $70.5M | $50.9M | $51.2M | $7.6M |
| Placements à Court Terme | 0 | 0 | 0 | 0 | $76.3M | 0 | 0 | 0 | 0 | 0 |
| Créances | 0 | 0 | $1.0M | $13.1M | $9.9M | $17.5M | $6.5M | $236000 | 0 | 0 |
| Stocks | 0 | 0 | $4.1M | $4.6M | $5.2M | $8.6M | 0 | 0 | 0 | 0 |
| Actifs Courants | $45.6M | $115.2M | $177.0M | $105.5M | $171.4M | $124.4M | $85.9M | $52.9M | $52.8M | $9.5M |
| Immobilisations Corporelles | $594000 | $786000 | $31.7M | $32.5M | $31.0M | $4.0M | $416000 | $2.8M | $2.4M | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $46.3M | $116.1M | $221.0M | $154.3M | $221.6M | $139.4M | $86.8M | $55.9M | $55.5M | $9.5M |
| Dettes Fournisseurs | $997000 | $1.2M | $5.4M | $2.5M | $1.7M | $4.9M | $2.3M | $919000 | $628000 | $986000 |
| Dette à Court Terme | $556000 | $6.7M | 0 | 0 | 0 | 0 | $5.0M | 0 | $10.3M | 0 |
| Passifs Courants | $5.5M | $14.5M | $17.0M | $24.8M | $22.2M | $37.4M | $25.7M | $8.3M | $17.0M | $2.5M |
| Dette à Long Terme | $9.1M | $12.0M | $70.2M | $71.2M | $72.2M | $78.9M | $37.9M | $34.2M | $20.1M | 0 |
| Passifs Totaux | $134.1M | $26.5M | $116.0M | $124.6M | $121.6M | $122.6M | $67.8M | $48.4M | $43.2M | $2.5M |
| Réserves | -$92.1M | -$134.4M | -$201.1M | -$295.5M | -$399.8M | -$542.4M | -$587.2M | -$629.4M | -$667.9M | -$694.9M |
| Capitaux Propres | -$87.8M | $89.7M | $105.0M | $29.7M | $100.0M | $16.8M | $19.0M | $7.5M | $12.3M | $7.0M |
| Dette Totale | $9.7M | $18.7M | $99.4M | $101.2M | $100.9M | $80.2M | $43.0M | $36.3M | $32.3M | 0 |
| Dette Nette | -$35.8M | -$95.9M | -$71.5M | $15.7M | -$52.6M | -$11.9M | -$27.5M | -$14.6M | -$18.9M | -$7.6M |
| Fonds de Roulement | $40.1M | $100.8M | $160.0M | $80.7M | $149.2M | $86.9M | $60.3M | $44.5M | $35.8M | $7.0M |
Santé financière
| Dette / Capitaux propres | 0.00 |
| Ratio de liquidité | 6.88 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -60.75 |
Rentabilité
| Rentabilité des capitaux propres | -222.32% |
| Rentabilité du capital investi | -232.05% |
| Rentabilité des actifs | -95.26% |
| Marge brute | 0.00% |
| Marge opérationnelle | 0.00% |
| Marge nette | 0.00% |
Entreprises liées: ABP · AIM · CANF · ENSC · IBO · KTTA · OGEN
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de KALA: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions